Amalia-Andrea Titieanu
Research Subjects
Amalia-Andrea Titieanu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Angela Smaranda Dascalescu
Department of Hematology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
2 shared publications - Vlad-Andrei Cianga
Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iași, Romania
2 shared publications Catalin Danaila
1 shared publicationCatalin Doru Danaila
1 shared publicationCosmin Minciuna
1 shared publicationDiana-Marina Fortoes
1 shared publication
Latest Publications
- 24 March 2025
- Published by Societatea Romana de Hematologie in Documenta Haematologica - Revista Romana de Hematologie
- Vol. 3 (2) , 67-72
The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed / Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
Aim: To assess the real-world efficacy of brentuximab vedotin and PD-1 inhibitors versus historical chemotherapy-only salvage regimens in relapsed/refractory classic Hodgkin lymphoma. Methods: Retrospective single-center study of two cohorts (n=30 each) treated between 1996–2012 (historical) and 2017–2021 (immunotherapy), with survival endpoints (OS, PFS, EFS1-3) analyzed by Kaplan–Meier and log-rank tests. Results: The immunotherapy group achieved a higher overall response rate (80% vs. 36.7%, p=0.001), longer median OS (47 vs. 30 months) and superior EFS1–3 (33 vs. 16 months, 32.5 vs. 8 months, 38 vs. 23 months; all p 0.05) compared to historical controls. Conclusion: Incorporation of brentuximab vedotin and PD-1 blockade before and after autologous SCT significantly improves response and survival outcomes in relapsed/refractory Hodgkin lymphoma, supporting earlier use of these agents in salvage and frontline settings.
- 24 March 2025
- Published by Societatea Romana de Hematologie in Documenta Haematologica - Revista Romana de Hematologie
- Vol. 3 (2) , 67-72
The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed / Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
Aim: To assess the real-world efficacy of brentuximab vedotin and PD-1 inhibitors versus historical chemotherapy-only salvage regimens in relapsed/refractory classic Hodgkin lymphoma. Methods: Retrospective single-center study of two cohorts (n=30 each) treated between 1996–2012 (historical) and 2017–2021 (immunotherapy), with survival endpoints (OS, PFS, EFS1-3) analyzed by Kaplan–Meier and log-rank tests. Results: The immunotherapy group achieved a higher overall response rate (80% vs. 36.7%, p=0.001), longer median OS (47 vs. 30 months) and superior EFS1–3 (33 vs. 16 months, 32.5 vs. 8 months, 38 vs. 23 months; all p 0.05) compared to historical controls. Conclusion: Incorporation of brentuximab vedotin and PD-1 blockade before and after autologous SCT significantly improves response and survival outcomes in relapsed/refractory Hodgkin lymphoma, supporting earlier use of these agents in salvage and frontline settings.
- 18 August 2023
- Published by Societatea Romana de Hematologie in Documenta Haematologica - Revista Romana de Hematologie
- Vol. 1 (2) , 43-49
Prognostic Significance of the Number of Copy Numbervariations by Mlpa Technique in Acute Lymphoblastic Leukemia
- 18 August 2023
- Published by Societatea Romana de Hematologie in Documenta Haematologica - Revista Romana de Hematologie
- Vol. 1 (2) , 43-49
Prognostic Significance of the Number of Copy Numbervariations by Mlpa Technique in Acute Lymphoblastic Leukemia